Digital inhalers may help predict occurrence of acute exacerbations of COPD for patients in an ambulatory setting.

While it trails Johnson & Johnson’s Tecvayli, Regeneron still hopes Lynozyfic can differentiate in terms of dosing ...

The main pharmacological interventions for palliation of breathlessness would be opioids, ie, oromorph and benzodiazepines ...

Research shows that digital inhalers equipped with remote monitoring capabilities may aid in predicting and identifying ...

With the demand for affordable health care rising across Ohio, health officials are cautioning that funding for free and ...

Pulmonary rehabilitation is initiated and completed by a greater proportion of patients with IPF vs COPD or other chronic respiratory disorders.

Breakthrough bioconvergence platform detects inflammatory events prior to symptoms, partnering with Altesa Biosciences to ...

Bronchiectasis causes your airways, called bronchi, to become damaged and widened over time. When you have bronchiectasis, ...

In February 2025 Harbour BioMed announced that the IND application for HBM9378 (SKB378), a TSLP-targeting monoclonal antibody ...

The FDA recently approved mepolizumab for treating adults with inadequately controlled COPD and an eosinophilic phenotype, ...

It is becoming increasingly recognized that people with COPD have an elevated risk of serious CV events,1 discussed Hanania ...

In smokers with COPD, LABA+LAMA is more effective than LABA+ICS in preventing exacerbations, regardless of blood eosinophil count.